Antibody therapies augment the naturally occurring antibodies in our immune system that help the immune system recognize infections.1,2,3 Antibodies have been developed to help identify and attack malignant cells in multiple myeloma, and in other cancers. Multiple novel combinations of antibody therapeutics are now available for the management of multiple myeloma. These include:
Bispecific antibodies can help bring together T cells, which are immune cells involved in targeting and destroying cancer cells, and specific receptors on cancer cells. In this way, bispecific antibodies can help the immune system recognize and destroy cancer.
One key target on cancer cells in multiple myeloma is BCMA, which is generally expressed to a greater degree on abnormal plasma cells than normal plasma cells.4 Three bispecific antibodies targeting BCMA have been approved for the treatment of multiple myeloma, including teclistamab, elranatamab, and linvoseltamab. Another bispecific antibody, talquetamab, targets GPRC5D.1 Other bispecific antibodies targeting BCMA are in active development for multiple myeloma, including5-10 :
While multiple antibody therapies have been incorporated in the National Comprehensive Cancer Institute (NCCN) guidelines for the treatment of multiple myeloma, these guidelines also support enrollment in clinical trials of new therapies. Discussing therapies in development for multiple myeloma with your physician might give rise to consideration of clinical trial opportunities in developing lines of therapy.11
All URLs accessed April 22, 2025
